Head lice in progress: what could/should be done-a report on an in vivo and in vitro field study

Head lice infections are a growing problem in the light of increasing migration of large population as well as the increasing current refugee flows and concomitant poor hygienic conditions. These infections are associated with a significantly reduced quality of life and frequent medical consultations. The approved drugs for the treatment of head lice infections have some disadvantages in the treatment despite their good efficacy. In addition to irritant-toxic substances that can cause adverse reactions in patients, a partial development of resistance has occurred and a double application is necessary to achieve adequate efficacy. For this reason, we have decided to test a product without the aforementioned treatment drawbacks. We examined the effect of Licener® on the head lice treatment through individual therapy trials. We identified 65 patients with head lice infections for the treatment with Licener®. All patients were treated with Licener® and visited for a period of 2 weeks. Successfully treated patients had no relapses. Against the background of this study and based on the observations of our applications, we expect that Licener® could enhance considerably the therapeutic options for the treatment of head lice infections, as an alternative to classical products.